- Home
- ZIP vs AMRN Comparison
ZIP vs AMRN Comparison
Compare ZIP & AMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZIP | AMRN |
|---|---|---|
| Founded | 2010 | 1989 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 305.7M | 342.8M |
| IPO Year | 2021 | 1998 |
Fundamental Metrics
Financial Performance| Metric | ZIP | AMRN |
|---|---|---|
| Price | $3.90 | $13.93 |
| Analyst Decision | Hold | Strong Sell |
| Analyst Count | 4 | 1 |
| Target Price | $3.88 | ★ $12.00 |
| AVG Volume (30 Days) | ★ 767.1K | 82.2K |
| Earning Date | 05-07-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 55.00 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $448,952,000.00 | $181,104,000.00 |
| Revenue This Year | $1.00 | N/A |
| Revenue Next Year | $5.93 | $1.26 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 39.22 |
| 52 Week Low | $1.65 | $12.96 |
| 52 Week High | $5.61 | $20.90 |
Technical Indicators
Market Signals| Indicator | ZIP | AMRN |
|---|---|---|
| Relative Strength Index (RSI) | 54.97 | 35.71 |
| Support Level | $3.85 | $13.58 |
| Resistance Level | $4.16 | $17.04 |
| Average True Range (ATR) | 0.23 | 0.59 |
| MACD | -0.01 | -0.23 |
| Stochastic Oscillator | 44.60 | 13.07 |
Price Performance
Historical ComparisonAbout ZIP ZipRecruiter Inc.
ZipRecruiter Inc is an online employment marketplace that connects job seekers and employers through an AI-powered platform. The company provides recruiting solutions that help employers identify and hire qualified candidates while enabling job seekers to discover relevant job opportunities through intelligent matching and recommendation tools.
About AMRN Amarin Corporation plc
Amarin Corp PLC is a pharmaceutical company. The company is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa. The company focuses on treatments to stop cardiovascular disease causing death, by providing patients, doctors and investors with reliable cardiovascular treatment options. Geographically, the company derives maximum revenue from United States.